Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oral combination therapy for type 2 diabetes.

Guillaume Charpentier1

  • 1Center Hospitalier Régional Gilles de Corbeil, Corbeil, France. kerbonac@noos.fr

Diabetes/Metabolism Research and Reviews
|September 27, 2002
PubMed
Summary

Oral monotherapy for type 2 diabetes often fails over time. Combination drug therapy provides better blood glucose control for many patients, especially those with high initial glucose levels.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intent to Treat Analysis of the Primary and Secondary Outcomes for the ODINN Intact Fish Skin Graft for Deep Diabetic Foot Wounds Trial.

International wound journal·2026
Same author

Intact fish skin graft for deep diabetic foot ulcers: results from the KEREFISH randomized controlled trial.

Diabetes & metabolism·2025
Same author

Emotional distress as a therapeutic target against persistent poor glycaemic control in subjects with type 1 diabetes: A systematic review.

Diabetes, obesity & metabolism·2025
Same author

Optimization of insulin management during postprandial and post-absorptive exercise in adults with type 1 diabetes: DiabraAlgo effectiveness in real life ?

Diabetes research and clinical practice·2025
Same author

Monoallelic pathogenic variants in LEPR do not cause obesity.

American journal of human genetics·2024
Same author

Intact Fish Skin Graft to Treat Deep Diabetic Foot Ulcers.

NEJM evidence·2024

Area of Science:

  • Endocrinology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Oral monotherapy for type 2 diabetes (T2D) shows initial efficacy but high secondary failure rates.
  • Primary failure of monotherapy is linked to high baseline blood glucose levels.

Purpose of the Study:

  • To evaluate the effectiveness of combination oral pharmacologic therapy for type 2 diabetes.
  • To assess the benefits of combination therapy compared to monotherapy in achieving glycemic control.

Main Methods:

  • Review of existing literature on oral antidiabetic agents and their combinations.
  • Analysis of treatment outcomes for patients with type 2 diabetes using monotherapy versus combination therapy.

Main Results:

  • Combination therapies (e.g., sulfonylurea plus metformin, thiazolidinedione, or acarbose; metformin plus thiazolidinedione or acarbose) achieve greater blood glucose reduction than maximal doses of single agents.
  • Combination treatment is effective in patients who have failed oral monotherapy.

Conclusions:

  • Combination oral drug regimens should be considered for initial treatment in symptomatic type 2 diabetes patients uncontrolled by diet alone.
  • Addressing high primary and secondary failure rates of monotherapy is crucial for effective type 2 diabetes management.

Related Experiment Videos